Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 3,574 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: T cells Clear all

Conditions: Small Cell Lung Carcinoma, Neuroendocrine Neoplasms, Extra-pulmonary Neuroendocrine Carcinoma
Interventions: BI 764532, dose 1, BI 764532, dose 2, Ventana DLL3 RxDx assay; Drug · Device
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 16
States / cities: Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 13 more

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: cilengitide; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Cancer
Interventions: COVID-19 Vaccination; Biological
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 2,206 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Carmel, Indiana • Indianapolis, Indiana

Conditions: Viral Infections After HSCT
Interventions: VSTs; Biological
Lead sponsor: Catherine Bollard; Other
Eligibility: 4 Weeks to 45 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: T-Cell Immune Deficiency Diseases, Severe Combined Immunodeficiency
Interventions: Busulfan, Fludarabine and ATG; Drug
Lead sponsor: Emory University; Other
Eligibility: Not listed
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2006
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myeloid Sarcoma, Chronic Myelogenous Leukemia (CML), Juvenile Myelomonocytic Leukemia (JMML), Myelodysplastic Syndrome (MDS), Non-Hodgkin Lymphoma (NHL)
Interventions: Cyclophosphamide, Fludarabine, G-CSF, Interleukin-2, Melphalan, Thiotepa, Rituximab, Natural killer cell therapy, T-cell depleted HPC transplant, CD45RA-depleted HPC transplant; Drug · Biological
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Scleroderma, Systemic
Interventions: Thalidomide, Placebo thalidomide; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: Hodgkin Disease, Non Hodgkin Lymphoma, Lymphoepithelioma, Severe Chronic Active EBV Infection Syndrome (SCAEBV), Leiomyosarcoma
Interventions: LMP1/2 CTLs (Group A), LMP1/2 CTLs (Group B); Drug
Lead sponsor: Catherine Bollard; Other
Eligibility: Not listed
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: HIV Infections
Interventions: [18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine); Drug
Lead sponsor: CellSight Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Myeloma Multiple
Interventions: Descartes 08; Biological
Lead sponsor: Cartesian Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Orange, California • Nashville, Tennessee

Conditions: Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions: ipilimumab, laboratory biomarker analysis; Biological · Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 2
States / cities: New Brunswick, New Jersey • Portland, Oregon

Conditions: Relapsed/Refractory B-cell Lymphomas, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Chronic Lymphocytic Leukemia (CLL), Marginal Zone Lymphoma (MZL), Mantle Cell Lymphoma (MCL), Small Lymphocytic Lymphoma (SLL), Primary Mediastinal Large B Cell Lymphoma, Transformed Follicular Lymphoma, Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma, Burkitt Lymphoma
Interventions: CLBR001 and SWI019; Combination Product
Lead sponsor: Calibr, a division of Scripps Research; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 8
States / cities: Duarte, California • San Diego, California • Chicago, Illinois + 5 more

Conditions: Diffuse Large B-cell Lymphoma
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 613 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Leukemia, Acute Lymphocytic Leukemia
Interventions: Velcade; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Stanford, California

Conditions: Lymphoma, T-Cell, Cutaneous
Interventions: Quisinostat, 12 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Neurotoxicity, Neurotoxicity Syndromes, Hematologic Malignancy, Immune Effector Cell Associated Neurotoxicity Syndrome
Interventions: DCog Short; Behavioral
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Ovarian Cancer
Interventions: Follicle Stimulating Hormone Receptor T Cells; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Interstitial Lung Disease, Common Variable Immunodeficiency
Interventions: Abatacept, Placebo; Drug · Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 4 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 6
States / cities: San Francisco, California • Tampa, Florida • Burlington, Massachusetts + 3 more

Conditions: Multiple Myeloma
Interventions: PHE885; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 6
States / cities: Palo Alto, California • Atlanta, Georgia • Boston, Massachusetts + 3 more

Conditions: Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Total-Body Irradiation, Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8; Procedure · Drug · Radiation
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Systemic Sclerosis (SSc), Systemic Sclerosis, Systemic Sclerosis (Scleroderma), Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria, Systemic Sclerosis Pulmonary, Systemic Sclerosis With Lung Involvement
Interventions: C-CAR168; Biological
Lead sponsor: AbelZeta Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Gilbert, Arizona

Conditions: Lymphoproliferative Malignancies, Acute Myeloid Leukemia
Interventions: ZEN003365; Drug
Lead sponsor: Zenith Epigenetics; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 4
States / cities: St Louis, Missouri • New York, New York • Springfield, Oregon + 1 more

Conditions: T-LGL Lymphoproliferative Disorders
Interventions: Alemtuzumab (Campath); Biological
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 85 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Acute (Cellular) Renal Allograft Rejection
Interventions: rATG; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer

Immune Responses in Oncology Patients to Novel Coronavirus Vaccines (IROC)

Allogeneic Virus-specific T Cell Lines (VSTs)

IMM 0212: Busulfan With Fludarabine and Antithymocyte Globulin as Preparative Therapy for Hematopoietic Stem Cell Transplant for the Treatment of Severe Congenital T-Cell Immunodeficiency

Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation

Thalidomide for Decreasing Collagen Biosynthesis in People With Progressive Systemic Sclerosis

Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma

Imaging Immune Activation in HIV by PET-MR

Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy

Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T

Real-World HRU and Costs in DLBCL Pts With Tisa-cel and Axi-cel, a Medicare Study.

Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia

A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma

Assessing DCog Short for Neurotoxicity in CAR-T

Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer

Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease

PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma

90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma

C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Systemic Sclerosis (SSc) Refractory to Standard Therapy

Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML

Alemtuzumab (Campath) to Treat T-Large Granular Lymphocyte Leukemia

Single Dose rATG for Renal Allograft Rejection